Philips CPAP BiPAP Respironics recall lawsuit MDL 3014 claimant guide

Philips CPAP Respironics Recall Lawsuit MDL 3014: Claimant Guide 2026

Daylongs · May 21, 2026 · 7 min read

#MDL 3014 #Philips CPAP lawsuit #Respironics #PE-PUR foam #mass tort #recall lawsuit #medical device lawsuit

Disclaimer: This post is for general information only and not legal advice. Consult a licensed US attorney for your specific situation.

The Philips CPAP Recall: What Happened and Why It Matters

For millions of Americans with sleep apnea, a CPAP (Continuous Positive Airway Pressure) machine is not optional equipment — it is a nightly medical necessity. Philips Respironics was, until recently, the world’s largest CPAP manufacturer, with devices used by millions across the US and globally.

On June 14, 2021, Philips issued one of the most consequential medical device recalls in recent history. The company disclosed that PE-PUR (polyester-based polyurethane) sound abatement foam used inside certain CPAP, BiPAP, and mechanical ventilator devices was prone to degradation — and that degraded foam could release toxic particles and gases directly into the device’s air pathway, which patients breathe continuously during sleep.

The scale was staggering: up to 4 million devices may have been affected. People who used these machines every night for years may have been unknowingly inhaling harmful chemical compounds while they slept.

The PE-PUR Foam Problem: What Was Released?

The core science of the recall involves foam chemistry. PE-PUR foam — used for its sound-dampening properties — can break down over time, particularly when exposed to heat, humidity, and cleaning agents like ozone. When it degrades, it releases both solid foam particles and volatile organic compounds (VOCs) into the breathing circuit.

Chemicals of Concern

Chemical	Potential Health Effects
Toluenediamine (TDA)	Suspected carcinogen; liver toxicity
Diethylene glycol	Kidney and liver toxicity
Dimethyl diazine	Potential carcinogen
PE-PUR foam particles	Airway irritation, inflammation, lung damage

Short-term symptoms reported by users include cough, headaches, airway irritation, nausea, and sinus problems.

Long-term exposure claims center on cancers (particularly lung, pancreatic, liver) and serious respiratory disease — the basis for ongoing personal injury MDL litigation.

What Philips Knew — and When

A critical element of the litigation is the question of when Philips first became aware of the foam degradation issue. According to FDA inspection reports and media coverage:

Philips allegedly identified foam degradation concerns as early as 2015
In some international markets, earlier warnings were issued
In the US, no broad public recall was issued until June 2021

This approximately six-year gap between alleged internal knowledge and public disclosure forms the core of plaintiffs’ negligence and fraud theories. Attorneys argue Philips continued selling devices knowing users were being exposed to harmful substances.

MDL 3014: Structure of the Federal Litigation

Key Case Facts

Full case name: In re Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability Litigation, MDL No. 3014
Court: U.S. District Court, Western District of Pennsylvania
Judge: Chief Judge Joy Flowers Conti
Primary defendants: Philips RS North America LLC; Koninklijke Philips N.V. (Dutch parent company)

Two Litigation Tracks

The MDL is divided into two distinct tracks:

Track	Claim Type	Settlement Status
Economic Loss	Device replacement, out-of-pocket costs, economic damages	$479M settlement announced Sept. 2023
Personal Injury	Cancer, serious lung disease, other physical harm	Ongoing — no final resolution yet

The $479 Million Economic-Loss Settlement (September 2023)

In September 2023, Philips agreed to pay up to $479 million to resolve economic-loss class action claims. This settlement covers plaintiffs who:

Purchased or leased a recalled Philips CPAP/BiPAP/ventilator device
Suffered economic damages such as device replacement costs, alternative therapy costs, and related out-of-pocket expenses
Did not suffer (or are not claiming) personal physical injuries from the devices

Critical distinction: This settlement does not resolve personal injury claims for cancer, serious respiratory disease, or other physical harm. Those claims continue in separate personal injury litigation within MDL 3014.

Separately from civil litigation, the U.S. Department of Justice entered into a consent decree with Philips regarding manufacturing quality-control issues. The consent decree mandates compliance with specific manufacturing standards. For the exact terms, consult the DOJ’s official press release.

Recall Timeline

Date	Event
~2015	Philips allegedly aware internally of PE-PUR foam degradation issues
June 14, 2021	Official recall announcement: ~4 million devices, CPAP/BiPAP/ventilators
July 2021	FDA issues urgent medical device recall notice
2022	DOJ consent decree with Philips on manufacturing standards
September 2023	$479M economic-loss settlement announced
January 2024	Philips announces permanent exit from US CPAP/BiPAP market

Eligibility: Who May Have a Claim?

Economic-Loss Claims

You may qualify for the economic-loss settlement if you:

Used a Philips Respironics device included in the June 2021 recall
Suffered economic damages (replacement device costs, repair costs, etc.)
Meet the specific class definition and enrollment criteria of the settlement

Personal Injury Claims

You may have a personal injury claim if you:

Criterion	Details
Device use	Used a recalled Philips Respironics CPAP, BiPAP, or ventilator
Duration	Extended use prior to the June 2021 recall date
Health condition	Diagnosed with lung cancer, head/neck cancer, liver cancer, respiratory disease, or other conditions potentially linked to foam exposure
Causation	Timeline supports foam exposure as contributing factor

Statute of Limitations by State (Selected)

State	Products Liability SOL	Notes
Pennsylvania	2 years	W.D. PA hosts MDL
California	2 years	From diagnosis/discovery
Texas	2 years	From discovery
New York	3 years
Florida	2 years
Illinois	2 years

The June 2021 recall is widely known public information. Courts may hold the clock started running in 2021 for many claimants. Those who received a cancer diagnosis in 2021 or 2022 face pressing deadlines.

Hypothetical Claimant Scenarios

Scenario 1: Lung Cancer After Long-Term CPAP Use

Profile: Thomas, 68, used a Philips DreamStation 1 CPAP every night from 2016 to 2021. Non-smoker. Diagnosed with lung cancer in November 2022.

Analysis: Long-term use of recalled device; non-smoking status strengthens the alternative causation argument. Lung cancer is the primary claimed injury. Personal injury track in MDL 3014 is the appropriate route. November 2022 diagnosis + 2-year SOL in most states = deadline November 2024. If not already filed, attorney consultation is urgent.

Scenario 2: Economic Loss Only — Replacement Device Costs

Profile: Sandra, 52, used a Philips System One device. No cancer or serious illness, but spent $1,800 replacing her device after the recall. She also missed CPAP therapy during the transition, worsening her sleep apnea symptoms.

Analysis: Economic-loss class action settlement ($479M) is designed for claims like Sandra’s. Whether the settlement enrollment window is still open requires verification. An attorney or claims administrator can confirm current status.

Scenario 3: Respiratory Illness, No Cancer

Profile: Michael, 61, used a Philips BiPAP S/T device from 2013 to 2021. Has developed chronic respiratory issues (worsening asthma, recurrent bronchitis) since 2019. No cancer diagnosis.

Analysis: Personal injury claims include serious respiratory conditions beyond cancer. Michael’s pre-recall symptom onset (2019) and timeline overlap with the alleged 2015 knowledge creates a potentially strong claim. SOL analysis is critical — the 2021 recall public announcement may start the clock in his state.

How to Check If Your Device Is Recalled

Philips official recall site: www.philipssrc.com
FDA medical device recalls: Search “Philips Respironics” at www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm
Device serial number: Located on the back or bottom of your device

Key Takeaways

MDL 3014 (In re Philips Recalled CPAP) is in the Western District of Pennsylvania before Chief Judge Joy Flowers Conti.
Recall issued June 14, 2021 for ~4 million devices; PE-PUR foam degradation releases toxic particles and gases.
Philips allegedly knew about foam degradation since 2015 but did not broadly recall until 2021 — a core litigation theory.
$479M economic-loss settlement announced September 2023; personal injury claims (cancer, lung disease) continue separately.
Philips exited the US CPAP market permanently in January 2024.
Act immediately if you have a potential claim — statutes of limitations are likely running.

Disclaimer: This post is for general information only and not legal advice. Consult a licensed US attorney for your specific situation.

Which court is handling the Philips CPAP MDL?

MDL 3014 — In re Philips Recalled CPAP, Bi-Level PAP, and Mechanical Ventilator Products Liability Litigation — is centralized in the U.S. District Court for the Western District of Pennsylvania. Chief Judge Joy Flowers Conti presides. Verify current docket status on PACER.

When did Philips recall its CPAP devices?

Philips Respironics issued the formal recall on June 14, 2021, covering certain CPAP, BiPAP, and mechanical ventilator devices. The recall cited PE-PUR sound abatement foam that could degrade and release potentially toxic particles and gases into the device air pathway.

What is the $479 million settlement about?

In September 2023, Philips agreed to pay up to $479 million to resolve economic-loss class action claims — covering device replacement costs, out-of-pocket expenses, and related economic damages. This settlement does not cover personal injury claims (cancer, serious respiratory disease), which continue on a separate litigation track.

What toxic chemicals can PE-PUR foam release?

Degraded PE-PUR foam may release particles and gases including toluenediamine (possible carcinogen), diethylene glycol (kidney/liver toxin), and dimethyl diazine. Users inhaling these substances during sleep over extended periods may face elevated health risks.

Which devices are covered by the recall?

Recalled devices include multiple DreamStation, System One, and Dorma series CPAP, BiPAP, and ventilator models. Check your device serial number at Philips' official recall site (philipssrc.com) or the FDA's medical device recall database.

Did Philips know about foam degradation before the 2021 recall?

Per FDA inspection reports and news coverage, Philips was allegedly aware of foam degradation concerns as early as 2015 but did not issue a broad public recall in the US until June 2021. This alleged concealment is a central theory in personal injury lawsuits.

Has Philips stopped selling CPAPs in the US?

Yes. In January 2024, Philips announced it would permanently exit the US CPAP and BiPAP market. This decision is widely attributed to the financial and legal consequences of the recall.

What is the DOJ consent decree with Philips?

The U.S. Department of Justice and Philips entered into a consent decree addressing manufacturing quality-control issues. The consent decree (separate from civil personal injury litigation) requires Philips to comply with specific manufacturing standards going forward. See the DOJ's official announcement for details.

What health injuries can I claim?

Claimed injuries include lung cancer, head and neck cancers, liver cancer, pancreatic cancer, respiratory irritation, asthma, organ damage, and other health conditions attributed to inhaling degraded PE-PUR foam particles and gases.

Is the economic-loss settlement still accepting claims?

The $479M economic-loss settlement was announced in September 2023. Whether enrollment windows are still open depends on the current claims administration status. Consult a mass tort attorney or the settlement administrator for current deadlines.

Asbestos Trust Fund Claims for US Navy Veterans With Mesothelioma: 2026 Guide

Philips CPAP Respironics Recall Lawsuit MDL 3014: Claimant Guide 2026

The Philips CPAP Recall: What Happened and Why It Matters